A federal judge in the Eastern District of Pennsylvania has denied class certification to wholesalers of the narcolepsy drug Provigil who claimed that its maker, Cephalon, paid off Ranbaxy Laboratories to delay generic versions of the medication from entering the market.
U.S. District Judge Mitchell S. Goldberg of the Eastern District of Pennsylvania’s ruling comes nearly a year after the U.S. Court of Appeals for the Third Circuit revoked class status in the case and sent it back to Goldberg for a second look.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
